KOSDAQBiotech & Pharma041960

Komipharm International

₩8,420▲ 1.08%2026-11-18 close
Market Cap
₩628.3B
Turnover
₩800M
Volume
90K
Shares out.
74.6M
PER
—
PBR
8.4×
EPS
-₩94
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Animal vaccine sales carrying human drug R&D costs

Government-procured animal vaccine sales anchor revenue, while human drug R&D costs and convertible bond derivative valuation swings keep profits volatile.

  1. 1

    Revenue peaked at KRW 58.8 billion in 2024 and fell to KRW 52.5 billion in 2025 (down 10.7%), while operating profit dropped 68.3% to KRW 1.96 billion.

  2. 2

    The company swung to a KRW 7.21 billion net loss attributable to controlling shareholders in 2025, with human drug development costs and convertible bond derivative valuation losses booked in the year-end settlement.

  3. 3

    Q3 2026 posted an operating loss of KRW 1.27 billion and a KRW 4.31 billion net loss attributable to controlling shareholders, and the last four quarters total KRW 6.75 billion in such losses.

  4. 4

    Foot-and-mouth disease vaccine procurement contracts and overseas trials and exports of ASF and PED vaccines form the business core, while the human drug PAX-1 is seeking marketing approval in several countries.

  5. 5

    Of the KRW 72.1 billion total equity at year-end 2025, KRW 69.5 billion belonged to controlling shareholders, and the debt ratio fell from 97.6% in 2023 to 85.8% in 2025.

02

Business structure

Komipharm International, founded in 1972, is an animal medicine company that produces and sells roughly 140 animal health products, including vaccines, antibiotics and supplements, according to its company profile.

It distributes domestically through about 130 sales agents and exports vaccines and injectables to 39 countries across Asia and Europe.

According to JobKorea company data, the segment mix as of March 2026 was poultry vaccines (biological products) at 29%, antibacterial chemical agents at 27%, other chemical products at 12%, swine vaccines at 11%, and other at 21%, so vaccines and chemical products form the main axes.

Government procurement is the largest single customer channel. The foot-and-mouth disease vaccine PRO-VAC FMD began supply under a two-year KRW 12.1 billion procurement contract with the Public Procurement Service in September 2023, with actual supply totaling KRW 8.8 billion, or about KRW 4.4 billion a year.

In October 2025 the company disclosed a new supply contract of about KRW 6.1 billion with the same agency, and that contract lifted the animal vaccine backlog to more than KRW 8.5 billion as of end-October 2025.

In human drugs, PAX-1 is seeking marketing approval in Australia, Taiwan, Korea and the United States, and its clinical and SG&A costs are cited as limits on profitability. Headcount was 172 at the end of 2025. The structure pairs animal medicine sales with the cost burden of human drug investment.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩12.5B₩65,724,7280.5%
2025Q4₩11.9B-₩200M−2.0%
2026Q1₩11.9B₩300M2.5%
2026Q2₩16.7B₩1.6B9.8%
2026Q3₩12.1B-₩1.3B−10.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩39.8B-₩3.8B-₩6.5B−9.6%−10.7%70.2%
2023₩42.6B-₩6.3B-₩4B−14.7%−7.1%97.6%
2024₩58.8B₩6.2B₩13.1B10.5%21.1%87.3%
2025₩52.5B₩2B-₩7.2B3.7%−10.4%85.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue rose from KRW 39.8 billion in 2022 to KRW 42.6 billion in 2023 (up 7.2%) and then to KRW 58.8 billion in 2024 (up 37.8%), the largest year in the 2022 to 2025 span. Revenue then fell 10.7% to KRW 52.5 billion in 2025.

Operating results moved from an operating loss of KRW 3.8 billion in 2022 and KRW 6.27 billion in 2023 to operating profit of KRW 6.19 billion in 2024, a swing to profit.

Operating profit then dropped 68.3% to KRW 1.96 billion in 2025, and the operating margin went from -9.6% and -14.7% in 2022 and 2023 to 10.5% in 2024 and 3.7% in 2025. Net income attributable to controlling shareholders turned from a KRW 13.1 billion profit in 2024 to a KRW 7.21 billion loss in 2025.

Net income including non-controlling interests moved from KRW 14.7 billion in 2024 to a KRW 8.03 billion net loss in 2025.

Reporting on the 2025 year-end settlement cited a convertible bond derivative valuation loss of about KRW 6.45 billion and human drug development costs of about KRW 6.12 billion, both of which sit outside the sales line. Operating cash flow was KRW 8.85 billion in 2024 and -KRW 622 million in 2025.

Quarterly, Q3 2025 revenue was KRW 12.5 billion with operating profit of KRW 6.572 million, while Q4 2025 revenue of KRW 11.9 billion (down 4.7% from the prior quarter) came with an operating loss of KRW 241 million.

Q1 2026 posted revenue of KRW 11.9 billion, operating profit of KRW 301 million and net income attributable to controlling shareholders of KRW 857 million. Q2 2026 revenue rose to KRW 16.7 billion (up 39.9%) with operating profit of KRW 1.64 billion.

Q3 2026 revenue fell 27.4% to KRW 12.1 billion, and the company booked an operating loss of KRW 1.27 billion and a net loss attributable to controlling shareholders of KRW 4.31 billion, a wider loss than a year earlier. The last four quarters total KRW 6.75 billion in such losses.

05

Industry analysis

Domestic animal vaccine demand is weighted heavily toward government procurement. Press reports estimate the domestic foot-and-mouth disease vaccine market at about KRW 100 billion, and the company secures steady demand through public procurement.

Foot-and-mouth disease can severely hit livestock producers when it breaks out, which is why the government manages it systematically and vaccine demand moves with disease-control policy.

Procurement volumes vary from contract to contract, but the company has said it has renewed foot-and-mouth vaccine procurement contracts with the government every year. In overseas markets, African swine fever (ASF) vaccines are the key variable.

Press reports estimate the global ASF vaccine market at more than KRW 4 trillion. ASF is described as a disease with a fatality rate near 90% that causes heavy damage to pig farming in Southeast Asia. The company ran ASF live-vaccine trials in the Philippines and widened its trial areas to Vietnam.

Exports of the PED vaccine to China entered the initial stage in the second half of 2025. In animal vaccines, procurement bidding and distributor networks shape results, and the company's roughly 130 domestic sales agents form its distribution base.

The human drug pipeline is still in clinical stages, so near-term revenue contribution remains concentrated in animal medicines.

06

Outlook

Three pipelines are confirmed. First, ASF vaccine dosing and observation have run on three designated farms in the Philippines, and trial areas were expanded to Vietnam.

The company expects to obtain marketing approval once the trials are complete, and plans to pursue overseas market entry through local marketing authorization in the Philippines after clinical work ends. Second, the PED vaccine Pro-vac PED-Fc has entered the early stage of exports to China.

Third, the human drug PAX-1 is pursuing global marketing approval in Australia, Taiwan, Korea and the United States. The domestic foot-and-mouth vaccine contract ran from October 2025 to September 2026, and that period has already ended, so whether and at what size it is renewed will shape the revenue trend.

The animal vaccine backlog stood at more than KRW 8.5 billion at end-October 2025. With an operating loss already recorded in Q3 2026, the next checkpoint is how far human drug costs can be reduced while animal vaccine sales hold up.

Until overseas approvals arrive, human drug development costs are likely to keep flowing through the income statement.

07

Valuation

PER
—
PBR
8.4×
ROE
-9.3%
EPS
-₩94
BPS
₩1,003
Dividend per share
₩0

Valuation is hard to compare on earnings multiples given the current profit structure. Because controlling shareholders have posted net losses over the last four quarters, the price-to-earnings ratio is not calculated. Price-to-book therefore becomes the central reference point.

The price-to-book ratio fell from about 11 times at year-end 2020 to about 3 times at year-end 2024, then rose again by year-end 2025.

The year-end 2025 level is higher than the year-end 2024 level, which reads as a wider premium over net asset value against the KRW 69.5 billion of equity attributable to controlling shareholders. Cash dividends contribute little to shareholder returns.

Compared with multiples formed in the profitable years, how the ratio is read depends on whether profits recover. Earnings-based comparison becomes possible only if quarterly profits stabilize in the black after 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Government-procured revenue base

Foot-and-mouth vaccine supply runs through government procurement, and a new contract of about KRW 6.1 billion was disclosed in October 2025. The timing of when this contract is recognized as revenue in coming quarters is the next point to check.

The company has said it renews foot-and-mouth vaccine procurement contracts with the government every year. A press estimate of about KRW 100 billion for the domestic market helps frame the size of this revenue base.

Overseas vaccine pipeline

ASF vaccine trials ran on three designated farms in the Philippines and were extended to Vietnam. The company expects marketing approval once the trials end. PED vaccine exports to China entered the initial stage in the second half of 2025.

A press estimate of the global ASF vaccine market at more than KRW 4 trillion indicates the scale of the potential opportunity.

Signs of profit recovery

The operating margin moved from -14.7% in 2023 to 10.5% in 2024 and 3.7% in 2025. Q1 2026 returned to profit with operating profit of KRW 301 million and net income attributable to controlling shareholders of KRW 857 million, and Q2 2026 revenue rose 39.9% from the prior quarter to KRW 16.7 billion. The debt ratio fell from 97.6% in 2023 to 85.8% in 2025.

09

Bear factors

Burden of human drug development costs

The 2025 year-end settlement reflected human drug development costs of about KRW 6.12 billion. Analysts noted through the first nine months of 2025 that new drug development costs limited reported results.

Q3 2026 recorded an operating loss of KRW 1.27 billion, and the last four quarters total KRW 6.75 billion in net losses attributable to controlling shareholders.

Profit volatility and uneven quarterly sales

A convertible bond derivative valuation loss of about KRW 6.45 billion was booked in the 2025 settlement, moving net income sharply. Revenue reached KRW 16.7 billion in Q2 2026 and then fell 27.4% to KRW 12.1 billion in Q3. The wide swings between quarters make the earnings path harder to forecast.

Revenue decline and capital structure burden

Revenue fell 10.7% in 2025, and net income attributable to controlling shareholders swung to a KRW 7.21 billion loss. Total liabilities of KRW 61.9 billion at year-end 2025, set against KRW 72.1 billion of total equity, define the financial room for maneuvering.

The price-to-book ratio at year-end 2025 was higher than at year-end 2024, so the premium over net assets widened.

10

Risk factors

Government procurement and disease-control policy

A significant part of sales depends on government procurement contracts, so revenue moves with contract size and renewal timing. The October 2025 contract was fixed through September 2026. Foot-and-mouth disease control policy and outbreaks of livestock disease can also change vaccine demand. Because procurement volumes differ from contract to contract, they add to quarterly revenue swings.

Clinical and approval timelines

The commercial timing of the ASF vaccine and PAX-1 depends on clinical results and country-by-country approvals. In an earlier interview, the company said further R&D investment would be needed to secure final product approval for its new drug.

If trials slip, development costs could keep flowing through the income statement. Until approval timelines are confirmed by disclosure, the timing is difficult to gauge.

Capital structure and derivative valuation swings

Fair value swings in the convertible bond derivatives move reported profit with external variables. The roughly KRW 6.45 billion valuation loss booked in the 2025 settlement shows the same item can swing results again. The debt ratio of 85.8% in 2025 is lower than 97.6% in 2023 but remains elevated. Funding structure is central to financial stability.

11

What to watch next

  1. Around February 2027

    Release of provisional full-year 2026 results. The 2025 provisional results were announced on February 20, 2026. Checkpoints are the Q4 2026 operating result, the annual revenue change from 2025, and whether human drug development costs declined.

  2. By March 31, 2027

    Deadline for the 2026 annual business report. Items to verify include the confirmed full-year operating margin, net income attributable to controlling shareholders, the debt ratio, and the breakdown of convertible bond valuation gains and losses.

  3. Around May 2027

    Release of Q1 2027 results. Q1 2026 results were released on May 14, 2026. The key checkpoints are revenue trend in the first quarter after the foot-and-mouth vaccine contract period ended and whether profitability holds.

  4. 2027 onward (timing undetermined)

    Completion of ASF vaccine trials in the Philippines and local marketing authorization, results from the Vietnam trials, and national approval progress for PAX-1. No disclosed schedule has been set, so timing remains undetermined.

12

Overall view

Komipharm International's disclosed results peaked in 2024 with revenue of KRW 58.8 billion and operating profit of KRW 6.19 billion.

They then fell in 2025 to revenue of KRW 52.5 billion and operating profit of KRW 1.96 billion, and the company swung to a KRW 7.21 billion net loss attributable to controlling shareholders.

In 2026, Q1 returned to profit and Q2 revenue reached KRW 16.7 billion, but Q3 moved back to an operating loss of KRW 1.27 billion. The animal vaccine business rests on foot-and-mouth vaccine procurement contracts and overseas expansion of ASF and PED vaccines.

On the other side, human drug development costs for PAX-1 and convertible bond derivative valuation swings are adding to earnings volatility.

On the financial side, the debt ratio fell from 97.6% in 2023 to 85.8% in 2025, and of the KRW 72.1 billion total equity at year-end 2025, KRW 69.5 billion belongs to controlling shareholders.

Earnings multiples cannot be used for valuation at present, and the price-to-book ratio at year-end 2025 was higher than at year-end 2024, so the premium over net assets widened.

Strengths and weaknesses coexist, so the next checkpoints are the operating margin and net income attributable to controlling shareholders in the 2026 annual report, along with progress on overseas approvals.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. comp.wisereport.co.kr
  2. press9.kr
  3. news.nate.com
  4. saramin.co.kr
  5. comp.fnguide.com
  6. m.thebell.co.kr
  7. m.thinkpool.com
  8. ibtomato.com
  9. kpinfo.kr
  10. jobkorea.co.kr
  11. investing.com
  12. investing.com
  13. pflowmoney.com
  14. goinsider.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis